NEW YORK, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, today announced that William Ho, President and Chief Executive Officer of Incysus will present at the Biotech Showcase on Monday, January 13, 2020 at 3:15 p.m. Pacific Time. The conference will be held at the Hilton San Francisco Union Square, San Francisco, CA.
| Who: | William Ho, President and Chief Executive Officer, Incysus Therapeutics |
| What: | Incysus Therapeutics Presentation at Biotech Showcase 2020 |
| When: | Monday, January 13, 2020, 3:15 p.m. Pacific Time |
| Where: | Hilton San Francisco Union Square Franciscan B Ballroom (Ballroom Level) 333 O’Farrell Street, San Francisco, CA 94102 |
About Biotech Showcase
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry's largest gatherings and busiest weeks.
About Incysus Therapeutics, Inc.
Incysus is focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. By using genetically modified gamma-delta (γδ) T cells, the Company’s technology addresses the challenges that immunotherapies face targeting cold, low mutation cancers. Incysus’ immuno-oncology programs include activated and gene-modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells. Since the Company’s inception in early 2016, Incysus has received FDA clearance of two Investigational New Drug applications (INDs) and has initiated several cancer programs in early pre-clinical stages, including a checkpoint combination program. The Company’s first clinical program is targeted to leukemia and lymphoma and its second program is targeted for the treatment of newly diagnosed glioblastoma (GBM). Information about the Company’s clinical trial in GBM (NCT04165941) can be found here: http://bit.ly/2Xx5MN6 and for leukemia and lymphoma (NCT03533816) can be found here: http://bit.ly/2pyYFHq. For more information about the Company and its programs, visit www.incysus.com.
Forward Looking Statements
Certain statements herein concerning the Company’s future expectations, plans and prospects, including without limitation, the Company’s current expectations regarding its business strategy, product candidates, and clinical development process and timing, constitute forward-looking statements. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” the negative of these and other similar expressions are intended to identify such forward looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Company’s control. Consequently, actual future results may differ materially from the anticipated results expressed in such statements. In the case of forward-looking statements regarding investigational product candidates and continuing further development efforts, specific risks which could cause actual results to differ materially from the Company’s current expectations include: scientific, regulatory and technical developments; failure to demonstrate safety, tolerability and efficacy; final and quality controlled verification of data and the related analyses; expense and uncertainty of obtaining regulatory approval, including from the U.S. Food and Drug Administration; and the Company’s reliance on third parties, including licensors and clinical research organizations. Do not place undue reliance on any forward-looking statements included herein, which speak only as of the date hereof and which the Company is under no obligation to update or revise as a result of any event, circumstances or otherwise, unless required by applicable law.
Contact:
Incysus Therapeutics, Inc.
+1 646.600.6GDT
info@incysus.com
www.incysus.com